BILLERICA, Mass. / Aug 07, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended June 30, 2023.
Second Quarter Financial Highlights
“Since launching our corporate transformation, we’re pleased with the accelerating progress as evidenced by both financial and business results,” said Masoud Toloue, President and Chief Executive Officer of Quanterix. “In under a year, our talented team has implemented fundamental change to business operations, with cash flow break-even being a key milestone, that said, we intend to continue to invest in scaling and supporting the important work performed on our Simoa® platform, that we believe will change the way we understand, test, and treat neurological diseases.”
Operational and Business Highlights
Accelerating our leadership position in blood-based biomarkers:
Full Year Business Outlook
With accelerating corporate transformation efforts, management has increased full-year revenue expectations to be in the range of $110 to $116 million, GAAP gross margin percentage to be in the low 50s, and non-GAAP gross margin percentage to be in the high 40s. The Company also anticipates a lower 2023 cash burn, in the range of $30 to $35 million.
For additional information on the non-GAAP financial measures included in this press release, please see “Use of Non-GAAP Financial Measures” and “Reconciliation of GAAP to Non-GAAP Financial Measures” below.
Conference Call
In conjunction with this announcement, the Company will host a conference call on August 8, 2023 at 8:30 a.m. E.T. Click here to pre-register for the conference call and obtain your dial-in number and passcode.
Interested investors can also access the live webcast from the News & Events page within the Investors section of the Quanterix website at http://www.quanterix.com. An archived webcast replay will be available on the Company’s website for one year.
Financial Highlights
Quanterix Corporation | ||||||||||||||||
Consolidated Statements of Operations | ||||||||||||||||
(Unaudited and in thousands, except per share data) | ||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product revenue | $ | 19,692 |
| $ | 14,785 |
| $ | 38,979 |
| $ | 35,441 |
| ||||
| Service revenue | 10,552 |
| 8,548 |
| 19,131 |
| 17,358 |
| ||||||||
| Collaboration and license revenue | 629 |
| 92 |
| 997 |
| 178 |
| ||||||||
| Grant revenue | 156 |
| 75 |
| 378 |
| 75 |
| ||||||||
| Total revenues | 31,029 |
| 23,500 |
| 59,485 |
| 53,052 |
| ||||||||
| Costs of goods sold and services: | ||||||||||||||||
| Cost of product revenue | 7,236 |
| 9,921 |
| 14,269 |
| 20,667 |
| ||||||||
| Cost of service and other revenue | 4,655 |
| 4,868 |
| 9,152 |
| 9,115 |
| ||||||||
| Total costs of goods sold and services | 11,891 |
| 14,789 |
| 23,421 |
| 29,782 |
| ||||||||
| Gross profit | 19,138 |
| 8,711 |
| 36,064 |
| 23,270 |
| ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 5,946 |
| 6,625 |
| 10,666 |
| 13,659 |
| ||||||||
| Selling, general, and administrative | 21,591 |
| 27,045 |
| 42,474 |
| 52,757 |
| ||||||||
| Other lease costs | 1,162 |
| — |
| 1,938 |
| — |
| ||||||||
| Restructuring | — |
| — |
| (33 | ) | — |
| ||||||||
| Total operating expenses | 28,699 |
| 33,670 |
| 55,045 |
| 66,416 |
| ||||||||
| Loss from operations | (9,561 | ) | (24,959 | ) | (18,981 | ) | (43,146 | ) | ||||||||
| Interest income, net | 3,886 |
| 552 |
| 7,335 |
| 604 |
| ||||||||
| Other expense, net | (154 | ) | (358 | ) | (146 | ) | (575 | ) | ||||||||
| Loss before income taxes | (5,829 | ) | (24,765 | ) | (11,792 | ) | (43,117 | ) | ||||||||
| Income tax (expense) benefit | (235 | ) | (137 | ) | (375 | ) | 62 |
| ||||||||
| Net loss | $ | (6,064 | ) | $ | (24,902 | ) | $ | (12,167 | ) | $ | (43,055 | ) | ||||
| Net loss per common share, basic and diluted | $ | (0.16 | ) | $ | (0.67 | ) | $ | (0.33 | ) | $ | (1.17 | ) | ||||
| Weighted-average common shares outstanding, basic and diluted | 37,494 |
| 36,922 |
| 37,411 |
| 36,887 |
| ||||||||
Quanterix Corporation | ||||||
Consolidated Balance Sheets | ||||||
(Unaudited and in thousands) | ||||||
June 30, 2023 | December 31, 2022 | |||||
| ASSETS | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 329,525 | $ | 338,740 | ||
| Accounts receivable | 24,423 | 19,017 | ||||
| Inventory | 18,156 | 16,786 | ||||
| Prepaid expenses and other current assets | 6,954 | 6,860 | ||||
| Total current assets | 379,058 | 381,403 | ||||
| Restricted cash | 2,686 | 2,597 | ||||
| Property and equipment, net | 18,328 | 20,162 | ||||
| Intangible assets, net | 6,476 | 7,516 | ||||
| Operating lease right-of-use assets | 20,380 | 21,223 | ||||
| Other non-current assets | 2,282 | 1,298 | ||||
| Total assets | $ | 429,210 | $ | 434,199 | ||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 3,238 | $ | 3,836 | ||
| Accrued compensation and benefits | 7,525 | 10,658 | ||||
| Accrued expenses and other current liabilities | 6,777 | 5,133 | ||||
| Deferred revenue | 10,421 | 8,644 | ||||
| Operating lease liabilities | 3,986 | 2,687 | ||||
| Total current liabilities | 31,947 | 30,958 | ||||
| Deferred revenue, net of current portion | 1,304 | 1,415 | ||||
| Lease liabilities, net of current portion | 39,378 | 41,417 | ||||
| Other non-current liabilities | 1,225 | 1,469 | ||||
| Total liabilities | 73,854 | 75,259 | ||||
| Total stockholders’ equity | 355,356 | 358,940 | ||||
| Total liabilities and stockholders’ equity | $ | 429,210 | $ | 434,199 | ||
Use of Non-GAAP Financial Measures
To supplement our financial statements presented on a U.S. GAAP basis, we present non-GAAP gross profit, non-GAAP gross margin, non-GAAP total operating expenses, and non-GAAP loss from operations, which are calculated by including shipping and handling costs for product sales within cost of goods sold instead of within selling, general, and administrative expenses. Management uses these non-GAAP measures to evaluate our operating performance in a manner that allows for meaningful period-to-period comparison and analysis of trends in our business and our competitors. Management believes that presentation of these non-GAAP measures provides useful information to investors in assessing our operating performance within our industry and in order to allow comparability to the presentation of other companies in our industry where shipping and handling costs are included in cost of goods sold for products. Management also uses these non-GAAP measures as a factor in assessing our progress against the Restructuring Plan. The non-GAAP financial information presented here should be considered in conjunction with, and not as a substitute for, the financial information presented in accordance with U.S. GAAP.
Set forth below is a reconciliation of non-GAAP gross profit, non-GAAP gross margin, non-GAAP total operating expenses, and non-GAAP loss from operations to their most directly comparable GAAP financial measures.
Reconciliation of GAAP to Non-GAAP Financial Measures
| Quanterix Corporation | ||||||||||||||||
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures | ||||||||||||||||
(Unaudited and in thousands, except percentages) | ||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
| GAAP gross profit | $ | 19,138 |
| $ | 8,711 |
| $ | 36,064 |
| $ | 23,270 |
| ||||
| Shipping and handling costs (1) | (1,623 | ) | (1,868 | ) | (3,451 | ) | (3,649 | ) | ||||||||
| Non-GAAP gross profit | $ | 17,515 |
| $ | 6,843 |
| $ | 32,613 |
| $ | 19,621 |
| ||||
| GAAP revenue | $ | 31,029 |
| $ | 23,500 |
| $ | 59,485 |
| $ | 53,052 |
| ||||
| GAAP gross margin (gross profit as % of revenue) | 61.7 | % | 37.1 | % | 60.6 | % | 43.9 | % | ||||||||
| Non-GAAP gross margin (non-GAAP gross profit as % of revenue) | 56.4 | % | 29.1 | % | 54.8 | % | 37.0 | % | ||||||||
| GAAP total operating expenses | $ | 28,699 |
| $ | 33,670 |
| $ | 55,045 |
| $ | 66,416 |
| ||||
| Shipping and handling costs (1) | (1,623 | ) | (1,868 | ) | (3,451 | ) | (3,649 | ) | ||||||||
| Non-GAAP total operating expenses | $ | 27,076 |
| $ | 31,802 |
| $ | 51,594 |
| $ | 62,767 |
| ||||
| GAAP loss from operations | $ | (9,561 | ) | $ | (24,959 | ) | $ | (18,981 | ) | $ | (43,146 | ) | ||||
| Non-GAAP loss from operations | $ | (9,561 | ) | $ | (24,959 | ) | $ | (18,981 | ) | $ | (43,146 | ) | ||||
(1) Shipping and handling costs, which include freight and other activities costs associated with product shipments, net of charges passed on to the customer, are captured within operating expenses in our consolidated statements of operations. During the three months ended June 30, 2023 and 2022, we incurred $1.6 million and $1.9 million, respectively, of shipping and handling costs recorded within operating expenses. During the six months ended June 30, 2023 and June 30, 2022, we incurred $3.5 million and $3.6 million, respectively, of shipping and handling costs within operating expenses. |
About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is driving breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa ® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,200 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.
Forward-Looking Statements
The Company's current financial results, as discussed in this press release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements about Quanterix’ financial performance, including statements under the header “Full Year Business Outlook” set forth above, and are subject to a number of risks, uncertainties and assumptions. Forward-looking statements in this press release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release include, but are not limited to, those described in “Part I, Item 1A, “Risk Factors” in Quanterix’ Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 6, 2023. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
| Last Trade: | US$15.56 |
| Daily Change: | -0.03 -0.19 |
| Daily Volume: | 245,799 |
| Market Cap: | US$595.170M |
March 04, 2024 February 26, 2024 February 23, 2024 December 12, 2023 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MORE
